Overview

• GSK, the manufacturer of Flovent, a popular asthma inhaler, has confirmed that it will discontinue the production of all strengths of both Flovent HFA and branded Flovent Diskus at the start of 2024.
• The discontinued products will be replaced with generic versions that are nearly identical, containing the same medication in the same device with the same instructions.
• Medical providers who prescribe Flovent express concern about potential hurdles for patients in getting the generic version covered by insurance.
• GSK recommends patients refill their current Flovent prescriptions as soon as possible and discuss potential temporary substitutes with their medical providers.
• The discontinuation of Flovent is linked to changes in Medicaid rebates that would result in penalties for GSK due to previous price increases.